Gan & Lee Pharmaceuticals Co Ltd (603087) - Total Liabilities
Based on the latest financial reports, Gan & Lee Pharmaceuticals Co Ltd (603087) has total liabilities worth CN¥851.65 Million CNY (≈ $124.62 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gan & Lee Pharmaceuticals Co Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Gan & Lee Pharmaceuticals Co Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Gan & Lee Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Gan & Lee Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Coca-Cola Icecek AS
IS:CCOLA
|
Turkey | TL117.96 Billion |
|
Wangsu Science Tech
SHE:300017
|
China | CN¥1.85 Billion |
|
Genpact Limited
F:35G
|
Germany | €2.82 Billion |
|
Ningbo Ginlong Technologies Co Ltd Class A
SHE:300763
|
China | CN¥9.85 Billion |
|
Leo Group Co Ltd
SHE:002131
|
China | CN¥8.03 Billion |
|
Ameris Bancorp
NASDAQ:ABCB
|
USA | $23.08 Billion |
|
Hankook Tire Co.
KO:161390
|
Korea | ₩13.08 Trillion |
|
Turkcell Iletisim Hizmetleri AS
NYSE:TKC
|
USA | $248.39 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Gan & Lee Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Gan & Lee Pharmaceuticals Co Ltd (603087) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.99 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gan & Lee Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gan & Lee Pharmaceuticals Co Ltd (2013–2025)
The table below shows the annual total liabilities of Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥998.57 Million ≈ $146.12 Million |
+1.02% |
| 2024-12-31 | CN¥988.45 Million ≈ $144.64 Million |
+1.64% |
| 2023-12-31 | CN¥972.52 Million ≈ $142.31 Million |
-4.77% |
| 2022-12-31 | CN¥1.02 Billion ≈ $149.44 Million |
+48.87% |
| 2021-12-31 | CN¥686.02 Million ≈ $100.39 Million |
+20.55% |
| 2020-12-31 | CN¥569.09 Million ≈ $83.28 Million |
+2.38% |
| 2019-12-31 | CN¥555.88 Million ≈ $81.34 Million |
+31.05% |
| 2018-12-31 | CN¥424.18 Million ≈ $62.07 Million |
+3.97% |
| 2017-12-31 | CN¥408.00 Million ≈ $59.70 Million |
+17.22% |
| 2016-12-31 | CN¥348.06 Million ≈ $50.93 Million |
+6.96% |
| 2015-12-31 | CN¥325.41 Million ≈ $47.62 Million |
+98.20% |
| 2014-12-31 | CN¥164.18 Million ≈ $24.02 Million |
+65.29% |
| 2013-12-31 | CN¥99.33 Million ≈ $14.53 Million |
-- |
About Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more